Funding round
Kailera Therapeutics Series A
Kailera Therapeutics, which works in biopharmaceutical research and development in Waltham, raised $400M in a Series A round announced on 1 Oct 2024, led by Atlas Venture, Bain Capital Life Sciences and RTW Investments, at a $1.50B post-money valuation. 4 firms took part. It is Kailera Therapeutics' first venture round on record.
$400M
Amount raised
$1.50B
Post-money valuation
$1.10B pre-money
4
Investors
3 leads
27%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced Kailera Therapeutics at $1.50B after the new money. The $400M bought investors about 27% of the company. It is 40% of the $1.00B Kailera Therapeutics has raised in the venture rounds on record. Kailera Therapeutics raised again 12 months later: a Series B round of $600M in Oct 2025.
Kailera Therapeutics' funding rounds
Kailera Therapeutics has 2 venture rounds on record. This one is highlighted.
- Series A this round 1 Oct 2024, led by Atlas Venture, Bain Capital Life Sciences and RTW Investments $400M$1.50B post-money
- Series B 14 Oct 2025, led by Bain Capital Private Equity $600M
Investors
Who put money in
Atlas Venture, Bain Capital Life Sciences and RTW Investments led the round with 1 other firm.
Lead investors
- backs 43 venture-backed companies new investor
- Bain Capital Life Sciences new investor
- backs 17 venture-backed companies new investor
Also in the round
- Lyra Capital new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
104 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $27M, and this round was 15 times the median. The closest in time, other companies' Series A rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 7 Oct 2024 | $100M | not disclosed | Atlas Venture and The Chernin Group |
| Pharmaceutical Products | 31 Oct 2024 | $77M | not disclosed | Soleus Capital and Sands Capital |
| Pharmaceutical Products | 18 Oct 2024 | $13M | not disclosed | Newton Biocapital |
| Pharmaceutical Products | 30 Oct 2024 | $2.3M | not disclosed | Gobia Enterprises |
| Pharmaceutical Products | 31 Oct 2024 | $2.1M | not disclosed | not named |
| Pharmaceutical Products | 11 Sep 2024 | $103M | $310M | EQT |
| Pharmaceutical Products | 19 Sep 2024 | $65M | not disclosed | Cormorant Asset Management |
| Pharmaceutical Products | 18 Nov 2024 | $57M | not disclosed | EQT and MRL Ventures Fund |
Sources
Where this comes from
Reported by 2 sources.
Questions
Frequently asked
How much did Kailera Therapeutics raise in its Series A round?
Kailera Therapeutics raised $400M in its Series A round, announced in Oct 2024.
Who led Kailera Therapeutics' Series A round?
Atlas Venture, Bain Capital Life Sciences and RTW Investments led it, with Lyra Capital.
What was Kailera Therapeutics' valuation at the Series A round?
$1.50B post-money ($1.10B pre-money).
How does it compare with other Series A rounds in Pharmaceutical Products?
104 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $27M, and this round was 15 times the median.
Did Kailera Therapeutics raise again after this round?
Yes: a Series B round in Oct 2025 of $600M.